Led you obviously missed the point of my post. It was not to initiate a discussion of the obvious but rather a discussion of if and when a pharma with something to lose due to RVX's potential success might step in with an eye to risk management as much as opportunity. If we are to believe RVX management (which anyone invested obviously does) there is a growing pool of valuable IP which would at the very least limit the downside risk of making a preemptive move on RVX in order to protect an existing revenue stream. As far as taking time to gain traction should apabetalone succeed, I would agree that it wouldn't hit peak sales right out of the chute but I doubt if it would be a slow starter. I have been told by RVX management that with at least one US insurer that apabetalone would be a required drug to maintain coverage in the target population if RRR similar to post hoc results is achieved.